Notable Calls
RSS feedNotablecalls@gmail.com
Monday, March 31, 2008
Schering-Plough (NYSE:SGP): Buying it down 20% in pre mkt
Couple of firms comment on Schering-Plough (NYSE:SGP) following the ENHANCE trial results:
- Deutsche Bank is lowering their tgt to $21.50 from $25.50 saying the ack of new insight from theENHANCE results was no surprise, but the tone of the panel "discussion", NEJM commentary and ensuing media coverage was more negative than anticipated. Additional trauma for the JV franchise, with immediate volatility in Rx demand and declines in market share is the likely near term outcome in firm's view.
Based upon the fallout from the NEJM ENHANCE publication, and two published editorials, they suspect a new round of RX declines, and a more negative impact on SGP's earnings outlook. Specifically, the firm expects that the JV, which represents 80% of SGP's net income, may fall 25%, back to its levels in '06. This equates to a decline in '08 estimate from $1.47 to $1.22. Firm has tried to be appropriate, and conservative in their assessment, but obviously, only the RX data over the next several weeks will tell the story.
SGP's EPS may decline 12% this year, while EPS may only recover to a level 4% higher in '09 than the EPS the comany achieved in 2007.
- Lehman: SGP (2-EW/1-Pos, $19.30, PT$20, $29b) A Butler - Downgrade 1-OW to 2-EW - ACC panel commentary neg; greater total Rx decline; uncertainty of mgd care formulary position; JV income from Zetia/Vytorin (~60% of ’09 EPS) materially impacted; cut ’08 $1.67 to $1.40 (v $1.52 cons), ’09 init $1.59 (v $1.73 cons); cut tgt $35 to $20.
- Goldman Sachs downgrades to Neutral from Buy.
Notablecalls: SGP is down 20% in pre mkt (trading at $15.80 as I write this). I've been buying around that level. Why?
- The stock has been cut in half, mainly bc of concerns regarding Vytorin/Zetia. Yes, sales and EPS will be hit but it's priced in here.
- I believe this is the moment smart money has been waiting for. Last time we had an opportunity to buy SGP was around 2002 when Hassan came in an cut the dividend. I remember buying the stock below $14 in pre mkt. This was the low.
- You gotta buy healthcare here. It's one of the safe havens.
- Deutsche Bank is lowering their tgt to $21.50 from $25.50 saying the ack of new insight from theENHANCE results was no surprise, but the tone of the panel "discussion", NEJM commentary and ensuing media coverage was more negative than anticipated. Additional trauma for the JV franchise, with immediate volatility in Rx demand and declines in market share is the likely near term outcome in firm's view.
Based upon the fallout from the NEJM ENHANCE publication, and two published editorials, they suspect a new round of RX declines, and a more negative impact on SGP's earnings outlook. Specifically, the firm expects that the JV, which represents 80% of SGP's net income, may fall 25%, back to its levels in '06. This equates to a decline in '08 estimate from $1.47 to $1.22. Firm has tried to be appropriate, and conservative in their assessment, but obviously, only the RX data over the next several weeks will tell the story.
SGP's EPS may decline 12% this year, while EPS may only recover to a level 4% higher in '09 than the EPS the comany achieved in 2007.
- Lehman: SGP (2-EW/1-Pos, $19.30, PT$20, $29b) A Butler - Downgrade 1-OW to 2-EW - ACC panel commentary neg; greater total Rx decline; uncertainty of mgd care formulary position; JV income from Zetia/Vytorin (~60% of ’09 EPS) materially impacted; cut ’08 $1.67 to $1.40 (v $1.52 cons), ’09 init $1.59 (v $1.73 cons); cut tgt $35 to $20.
- Goldman Sachs downgrades to Neutral from Buy.
Notablecalls: SGP is down 20% in pre mkt (trading at $15.80 as I write this). I've been buying around that level. Why?
- The stock has been cut in half, mainly bc of concerns regarding Vytorin/Zetia. Yes, sales and EPS will be hit but it's priced in here.
- I believe this is the moment smart money has been waiting for. Last time we had an opportunity to buy SGP was around 2002 when Hassan came in an cut the dividend. I remember buying the stock below $14 in pre mkt. This was the low.
- You gotta buy healthcare here. It's one of the safe havens.
posted by notablecalls # 8:02 AM 
Archives
June 2006 July 2006 August 2006 September 2006 October 2006 November 2006 December 2006 January 2007 February 2007 March 2007 April 2007 May 2007 June 2007 July 2007 August 2007 September 2007 October 2007 November 2007 December 2007 January 2008 February 2008 March 2008 April 2008 May 2008 June 2008 July 2008 August 2008 September 2008 October 2008 November 2008 December 2008 January 2009 February 2009 March 2009 April 2009 May 2009 June 2009 July 2009
